Literature DB >> 12135707

Galectin-induced activation of the transcription factors NFAT and AP-1 in human Jurkat T-lymphocytes.

Hermann Walzel1, Matthias Blach, Jun Hirabayashi, Yoichiro Arata, Ken-ichi Kasai, Josef Brock.   

Abstract

Galectin-mediated ligation of glycoepitopes on T-cell activation markers induces an increase in the cytosolic calcium concentration ([Ca(2+)](i)) originating from a transient Ca(2+) release of internal stores as well as a sustained influx across the plasma membrane. In transiently transfected Jurkat T-lymphocytes, galectins [galectin-1 (gal-1), recombinant human galectin-1 (rec gal-1), nematode 32-kDa galectin (LEC-1), nematode 16-kDa galectin (LEC-6)] differentially stimulate the expression of the luciferase reporter gene constructs pNFAT-TA-Luc and pAP1(PMA)-TA-Luc, which are activated by the nuclear factor of activated T-cells (NFAT) or the transcription factor, activator protein 1 (AP-1), respectively. The galectin-stimulated expression of the reporter constructs is completely inhibited by lactose (30 mM) and asialofetuin (30 microM) carrying Galbeta1-4GlcNAc sequences. Preincubation of pNFAT-TA-Luc-transfected cells with cyclosporine A (0.1 microM) and FK506 (0.01 microM) abrogated the gal-1-induced expression of the reporter luciferase (Luc). Electrophoretic mobility shift assays (EMSAs) provided evidence for gal-1-stimulated increase in the binding of nuclear extracts to a synthetic oligonucleotide with an AP-1 consensus sequence. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135707     DOI: 10.1016/s0898-6568(02)00035-9

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

Review 1.  The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders.

Authors:  J M Ilarregui; G A Bianco; M A Toscano; G A Rabinovich
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

2.  Galectin-1 induced activation of the apoptotic death-receptor pathway in human Jurkat T lymphocytes.

Authors:  Bettina Brandt; Tom Büchse; Ehab Fathi Abou-Eladab; Markus Tiedge; Eberhard Krause; Udo Jeschke; Hermann Walzel
Journal:  Histochem Cell Biol       Date:  2008-02-21       Impact factor: 4.304

3.  Quantifying protein interface footprinting by hydroxyl radical oxidation and molecular dynamics simulation: application to galectin-1.

Authors:  Olga Charvátová; B Lachele Foley; Marshall W Bern; Joshua S Sharp; Ron Orlando; Robert J Woods
Journal:  J Am Soc Mass Spectrom       Date:  2008-07-18       Impact factor: 3.109

4.  Galectin-1 induced activation of the mitochondrial apoptotic pathway: evidence for a connection between death-receptor and mitochondrial pathways in human Jurkat T lymphocytes.

Authors:  Falko Lange; Bettina Brandt; Markus Tiedge; Ludwig Jonas; Udo Jeschke; Ralf Pöhland; Hermann Walzel
Journal:  Histochem Cell Biol       Date:  2009-04-18       Impact factor: 4.304

5.  The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.

Authors:  Selvi Ramasamy; Sekhar Duraisamy; Sergei Barbashov; Takeshi Kawano; Surender Kharbanda; Donald Kufe
Journal:  Mol Cell       Date:  2007-09-21       Impact factor: 17.970

Review 6.  Galectin-1: a bifunctional regulator of cellular proliferation.

Authors:  Ken Scott; Cristina Weinberg
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

7.  Role of the JNK/c-Jun/AP-1 signaling pathway in galectin-1-induced T-cell death.

Authors:  B Brandt; E F Abou-Eladab; M Tiedge; H Walzel
Journal:  Cell Death Dis       Date:  2010       Impact factor: 8.469

8.  GARP: a key receptor controlling FOXP3 in human regulatory T cells.

Authors:  M Probst-Kepper; R Geffers; A Kröger; N Viegas; C Erck; H-J Hecht; H Lünsdorf; R Roubin; D Moharregh-Khiabani; K Wagner; F Ocklenburg; A Jeron; H Garritsen; T P Arstila; E Kekäläinen; R Balling; H Hauser; J Buer; S Weiss
Journal:  J Cell Mol Med       Date:  2009-05-13       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.